In earnings calls, diabetes tech companies had less to say about tariffs and focused more on future growth.

Embecta stock may seem undervalued at first glance, but heavy debt, declining pen needle revenues, and competition signal ...

Go-Pen ApS announced recently that it received FDA 510(k) clearance for its Go-Pen cost-effective, user-filled insulin pen.

The smaller Mobi pump for more active users was launched in 2024, and the Sigi patch pump is in development. With this range of products, we think it’s likely Tandem can address a wider swath of both ...